Related references
Note: Only part of the references are listed.Paromomycin
Robert N. Davidson et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2009)
Visceral leishmaniasis in eastern Africa - current status
Richard Reithinger et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2007)
Injectable paromomycin for visceral leishmaniasis in India
Shyam Sundar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection
K Ritmeijer et al.
CLINICAL INFECTIOUS DISEASES (2006)
The economic impact of visceral leishmaniasis on households in Bangladesh
DA Sharma et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2006)
Drug resistance in leishmaniasis
SL Croft et al.
CLINICAL MICROBIOLOGY REVIEWS (2006)
Visceral leishmaniasis: New health tools are needed
A Hailu et al.
PLOS MEDICINE (2005)
Sodium stibogluconate cardiotoxicity and safety of generics
S Rijal et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2003)
A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis
CP Thakur et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2000)
Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study
CP Thakur et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2000)
Share Paper
